Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL28

CCL28

Basics

Aliases:
This biomarker is also known as:
  • chemokine (C-C motif) ligand 28 splice variant chi,
  • Small-inducible cytokine A28,
  • CCK1,
  • C-C motif chemokine 28,
  • mucosae-associated epithelial chemokine,
  • SCYA28,
  • Mucosae-associated epithelial chemokine,
  • small inducible cytokine subfamily A (Cys-Cys), member 28,
  • Protein CCK1,
  • small-inducible cytokine A28,
  • MEC,
  • chemokine (C-C motif) ligand 28,
  • CC chemokine CCL28,
  • small inducible cytokine A28,

View in BioMuta

Description…

CCL28 is a member of the small cytokine CC subfamily, and is involved in immunoregulatory and inflammatory processes. CC cytokines are characterized by two adjacent cysteines. CCL28 functions as a chemotactic factor for resting CD4 or CD8 T cells and eosinophils. CCL28 binds to CCR3 and CCR10 and induces calcium mobilization in a dose-dependent manner.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

CCL28 was present at higher levels among cases compared to controls with reasonable AUC values.

Performance Comment

CCL28 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html